{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T14:39:53Z","timestamp":1774276793448,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T00:00:00Z","timestamp":1704240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T00:00:00Z","timestamp":1704240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Fakult\u00e4t Mannheim der Universit\u00e4t Heidelberg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Palliat Care"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Intranasal (i.n.) drug application is a widely known and low-invasive route of administration that may be able to achieve rapid symptom control in terminally ill patients. According to the German S3 guideline \u201cPalliative care for patients with incurable cancer\u201d, benzodiazepines, such as midazolam, are recommended for the treatment of terminal agitation. To the best of our knowledge there is no evidence for i.n. midazolam in terminally ill patients. We aim to assess the use of i.n. midazolam as an alternative to subcutaneous administration of the drug.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this monocentric, randomised, controlled, open-label investigator initiated trial, n\u2009=\u200960 patients treated at the palliative care unit of a University Hospital will be treated with 5\u00a0mg midazolam i.n. versus 5\u00a0mg subcutaneous (s.c.) midazolam in the control arm when terminal agitation occurs (randomly assigned 1:1). The estimated recruitment period is 18 months. Treatment efficacy is defined as an improvement on the Richmond Agitation Sedation Scale (Palliative Version) (RASS-PAL) and a study specific numeric rating scale (NRS) before and after drug administration. Furthermore, plasma concentration determinations of midazolam will be conducted at t<jats:sub>1<\/jats:sub>\u2009=\u20090\u00a0min, t<jats:sub>2<\/jats:sub>\u2009=\u20095\u00a0min, and t<jats:sub>3<\/jats:sub>\u2009=\u200920\u00a0min using liquid chromatography\/mass spectrometry (LC-MS). The primary objective is to demonstrate non-inferiority of midazolam i.n. in comparison to midazolam s.c. for the treatment of agitation in terminally ill patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>Midazolam i.n. is expected to achieve at least equivalent reduction of terminal agitation compared to s.c. administration. In addition, plasma concentrations of midazolam i.n. are not expected to be lower than those of midazolam s.c. and the dynamics of the plasma concentration with an earlier increase could be beneficial.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>German Clinical Trials Registry DRKS00026775, registered 07.07.2022, Eudra CT No.: 2021-004789-36.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12904-023-01330-1","type":"journal-article","created":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T05:03:23Z","timestamp":1704258203000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Treatment of agitation in terminally ill patients with intranasal midazolam versus subcutaneous midazolam: study protocol for a randomised controlled open-label monocentric trial (MinTU Study)"],"prefix":"10.1186","volume":"23","author":[{"given":"Hanna","family":"Hirschinger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evelyn","family":"Jaeger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanie","family":"Nittka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svetlana","family":"Hetjens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Lorenz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constanze","family":"Remi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne","family":"Saussele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolf-K.","family":"Hofmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deniz","family":"Gencer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"Boch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,3]]},"reference":[{"key":"1330_CR1","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/S1470-2045(08)70278-X","volume":"9","author":"F Nauck","year":"2008","unstructured":"Nauck F. Symptomkontrolle in Der Sterbephase. Lancet Oncol. 2008;9:1086\u201391.","journal-title":"Lancet Oncol"},{"key":"1330_CR2","volume-title":"Erweiterte S3 Leitlinie Palliativmedizin f\u00fcr Patienten Mit Einer Nicht-Heilbaren Krebserkrankung. Version 2.2 ed","author":"Leitlinienprogramm Onkologie","year":"2020","unstructured":"Leitlinienprogramm Onkologie. Erweiterte S3 Leitlinie Palliativmedizin f\u00fcr Patienten Mit Einer Nicht-Heilbaren Krebserkrankung. Version 2.2 ed. Berlin: Deutsche Gesellschaft f\u00fcr Palliativmedizin e.V.; 2020."},{"key":"1330_CR3","volume-title":"Leitfaden Palliative Care - Palliativmedizin und Hospizbegleitung","author":"C Bausewein","year":"2018","unstructured":"Bausewein C, Roller S, Voltz R. Leitfaden Palliative Care - Palliativmedizin und Hospizbegleitung. 6 ed. M\u00fcnchen: ELSEVIER; 2018.","edition":"6"},{"key":"1330_CR4","unstructured":"Bausewein C, R\u00e9mi C. Zum Umgang Mit off-label-use in Der Palliativmedizin. 2 ed: Kompetenzzentrum Palliativpharmazie Mit Zentralstelle off-label-use Klinik Und Poliklinik f\u00fcr Palliativmedizin. LMU Klinikum M\u00fcnchen; 2020."},{"key":"1330_CR5","unstructured":"Hagemann V, Bausewein C, R\u00e9mi C. Drug use beyond the licence in palliative care: a systematic review and narrative synthesis. Eur J Hosp Pharm. 2021:1\u20137."},{"key":"1330_CR6","doi-asserted-by":"crossref","unstructured":"Simon ST, Niemand A-M, Benalia H, Voltz R, Higginson IJ, Bausewein C. Acceptability and preferences of six different routes of drug application for Acute Breathlessness: a comparison study between the United Kingdom and Germany. J Palliat Med. 2012;15(12).","DOI":"10.1089\/jpm.2012.0249"},{"key":"1330_CR7","unstructured":"Takeda Pharma AS. Fachinformation Instanyl Nasenspray. 2021."},{"issue":"4","key":"1330_CR8","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1111\/bcp.13163","volume":"83","author":"L Schrier","year":"2017","unstructured":"Schrier L, Zuiker R, Merkus FWHM, Klaasen ES, Guan Z, Tuk B, et al. Pharmacokinetics and pharmacodynamics of a new highly concentrated intranasal midazolam formulation for conscious sedation. Br J Clin Pharmacol. 2017;83(4):721\u201331.","journal-title":"Br J Clin Pharmacol"},{"key":"1330_CR9","unstructured":"Daniels R. Nasalia - Applikationsroute Mit T\u00fccken. Pharmazeutische Ztg. 2017;162017."},{"issue":"7","key":"1330_CR10","first-page":"336","volume":"31","author":"A Kirchhoff","year":"2010","unstructured":"Kirchhoff A, Fehr-Bigger M, Moudry R, Guyer S. Aktuelles Aus Der Rezeptur: Midazolam-Nasenspray 25\u00a0mg\/ml. Krankenhauspharmazie. 2010;31(7):336\u20137.","journal-title":"Krankenhauspharmazie"},{"issue":"3","key":"1330_CR11","doi-asserted-by":"publisher","first-page":"244","DOI":"10.3109\/15360288.2010.493579","volume":"24","author":"TW LeBlanc","year":"2010","unstructured":"LeBlanc TW, Wheeler JL, Abernethy AP. Research in end-of-life settings: an ethical inquiry. J Pain Palliat Care Pharmacotherapy. 2010;24(3):244\u201350.","journal-title":"J Pain Palliat Care Pharmacotherapy"},{"key":"1330_CR12","unstructured":"Bundesministerium der Justiz. Arzneimittelgesetz (AMG). 1976."},{"key":"1330_CR13","unstructured":"European Medicines Agency (EMA). ICH E6 (R2) Good clinical practice - Scientific guideline 1995\u20132023 [Available from: https:\/\/www.ema.europa.eu\/en\/ich-e6-r2-good-clinical-practice-scientific-guideline."},{"key":"1330_CR14","unstructured":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte - Deutsches Institut f\u00fcr Medizinische Dokumentation und Information. Deutsches Register Klinischer Studien, Glossar, Studienphasen 2021 [Available from: https:\/\/www.dimdi.de\/dynamic\/de\/glossar\/glossareintrag\/Studienphasen\/."},{"key":"1330_CR15","unstructured":"ABDA \u2013 Bundesvereinigung Deutscher Apothekerverb\u00e4nde e. V. Deutscher Arzneimittelcodex, Neues Rezepturformularium, Rezepturenfinder, Midazolam-Nasenspray 25\u00a0mg\/ml 2021 [Available from: https:\/\/dacnrf.pharmazeutische-zeitung.de\/index.php?id=rezepturenfinderdetail&uid=3109."},{"issue":"1","key":"1330_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1472-684X-13-17","volume":"13","author":"SH Bush","year":"2014","unstructured":"Bush SH, Grassau PA, Yarmo MN, Zhang T, Zinkie SJ, Pereira JL. The Richmond agitation-sedation scale modified for palliative care inpatients (RASS-PAL): a pilot study exploring validity and feasibility in clinical practice. BMC Palliat Care. 2014;13(1):1\u20139.","journal-title":"BMC Palliat Care"},{"issue":"2","key":"1330_CR17","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1213\/01.ane.0000226150.90317.16","volume":"103","author":"DP Wermeling","year":"2006","unstructured":"Wermeling DP, Record KA, Kelly TH, Archer SM, Clinch T, Rudy AC. Pharmakokinetics and pharmacodynamics of a New Intranasal Midazolam Formulation in healthy volunteers. Anesth Analgesia. 2006;103(2):344\u20139.","journal-title":"Anesth Analgesia"},{"key":"1330_CR18","unstructured":"ABDATA Pharma-Daten-Service. ABDA Datenbank: Midazolam Wirkstoffdossier. 2021."},{"key":"1330_CR19","doi-asserted-by":"crossref","unstructured":"Schmacke N, Palliativmedizin. Ein Modell f\u00fcr comparative effectiveness research? Zeitschrift f\u00fcr Evidenz, Fortbildung Und Qualit\u00e4t Im Gesundheitswesen. 2012;106(7):484\u201391.","DOI":"10.1016\/j.zefq.2012.06.025"},{"key":"1330_CR20","unstructured":"Klinik f\u00fcr Palliativmedizin UF. Warum Forschung im Bereich Palliative Care? 2022 [Available from: http:\/\/www.uniklinik-freiburg.de\/palliativmedizin\/kompetenzzentrum\/projekte.html."},{"key":"1330_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-662-56588-9","volume-title":"Basiswissen Medizinische Statistik","author":"C Wei\u00df","year":"2019","unstructured":"Wei\u00df C. Basiswissen Medizinische Statistik. 7 ed. Berlin: Springer; 2019.","edition":"7"}],"container-title":["BMC Palliative Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12904-023-01330-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12904-023-01330-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12904-023-01330-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T17:03:23Z","timestamp":1704301403000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpalliatcare.biomedcentral.com\/articles\/10.1186\/s12904-023-01330-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,3]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1330"],"URL":"https:\/\/doi.org\/10.1186\/s12904-023-01330-1","relation":{},"ISSN":["1472-684X"],"issn-type":[{"value":"1472-684X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,3]]},"assertion":[{"value":"25 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Ethics approval: 2022-4 monocentre. Written, informed consent to participate will be obtained from all participants. We confirm that all experiments are performed in accordance with relevant guidelines and regulations (the Declaration of Helsinki and Good Clinical Practice). The trial was approved and registered by the regulatory authorities in accordance with the legal requirements.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"University of Heidelberg.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Trial sponsor"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"8"}}